Skip Nav Destination
Issues
15 October 2007
-
Cover Image
Cover Image
Immunofluorescent analysis of the effect of irradiation on the localization of PKR+/+ MEFs. PKR expression increased 4 hours after radiation therapy in PKR+/+ cells. Translocation of PKR was noted in the nucleus of PKR+/+ MEFs but was not seen in PKR-/- cells. Additionally, phosphorylated PKR was increased in the PKR+/+ cells suggesting activation of PKR after irradiation. For further details, please see Holzen et al. on page 6032 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
The Clinical Connection
Molecular Pathways
Human Cancer Biology
Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients
Maud Brousseau; Xavier Leleu; Jérémie Gerard; Thomas Gastinne; Alban Godon; Franck Genevieve; Mamoun Dib; Jean-Luc Lai; Thierry Facon; Marc Zandecki; for the Intergroupe Francophone du Myélome
The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor κB and Akt Activation
Urs von Holzen; Abujiang Pataer; Uma Raju; Dora Bocangel; Stephan A. Vorburger; Yanna Liu; Xiaolin Lu; Jack A. Roth; Bharat B. Aggarwal; Glen N. Barber; Khandan Keyomarsi; Kelly K. Hunt; Stephen G. Swisher
Imaging, Diagnosis, Prognosis
Synchronous Alterations of Wnt and Epidermal Growth Factor Receptor Signaling Pathways through Aberrant Methylation and Mutation in Non–Small Cell Lung Cancer
Makoto Suzuki; Hisayuki Shigematsu; Takahiro Nakajima; Rieko Kubo; Shinichiro Motohashi; Yasuo Sekine; Kiyoshi Shibuya; Toshihiko Iizasa; Kenzo Hiroshima; Yukio Nakatani; Adi F. Gazdar; Takehiko Fujisawa
High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients
Rui Henrique; Franclim R. Ribeiro; Daniel Fonseca; Mohammad O. Hoque; André L. Carvalho; Vera L. Costa; Mafalda Pinto; Jorge Oliveira; Manuel R. Teixeira; David Sidransky; Carmen Jerónimo
Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma
James P.B. O'Connor; Gordon C. Jayson; Alan Jackson; Dana Ghiorghiu; Bernadette M. Carrington; Chris J. Rose; Samantha J. Mills; Ric Swindell; Caleb Roberts; Claire L. Mitchell; Geoffrey J.M. Parker
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Richard D. Press; Chad Galderisi; Rui Yang; Carole Rempfer; Stephanie G. Willis; Michael J. Mauro; Brian J. Druker; Michael W.N. Deininger
Magnetic Resonance Imaging of the Breast Improves Detection of Invasive Cancer, Preinvasive Cancer, and Premalignant Lesions during Surveillance of Women at High Risk for Breast Cancer
Christopher C. Riedl; Lothar Ponhold; Daniel Flöry; Michael Weber; Regina Kroiss; Teresa Wagner; Michael Fuchsjäger; Thomas H. Helbich
DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma
Anjana A. Kulkarni; Marco Loddo; Elisabetta Leo; Mohammed Rashid; Kathryn L. Eward; Thomas R. Fanshawe; Jessica Butcher; Alison Frost; Jonathan A. Ledermann; Gareth H. Williams; Kai Stoeber
Cancer Therapy: Clinical
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma
John P. Leonard; Brian K. Link; Christos Emmanouilides; Stephanie A. Gregory; Daniel Weisdorf; Jeffrey Andrey; John Hainsworth; Joseph A. Sparano; Donald E. Tsai; Sandra Horning; Arthur M. Krieg; George J. Weiner
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Roy S. Herbst; Angela M. Davies; Ronald B. Natale; Thao P. Dang; Joan H. Schiller; Linda L. Garland; Vincent A. Miller; David Mendelson; Annick D. Van den Abbeele; Yulia Melenevsky; Daniel J. de Vries; David A. Eberhard; Benjamin Lyons; Stuart G. Lutzker; Bruce E. Johnson
Cancer Therapy: Preclinical
Cancer Susceptibility and Prevention
Letter to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.